Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey
2013 (English)In: Europace, ISSN 1099-5129, E-ISSN 1532-2092, Vol. 15, no 6, 915-918 p.Article in journal (Refereed) Published
This survey was conducted to provide an insight into the current clinical practice regarding the use of cardioversion for atrial fibrillation (AF) in Europe. Responses were received from 57 centres across Europe, 71.9% of which were university hospitals. For electrical cardioversion, general anaesthesia was managed by an anaesthesiologist in 73.9% of centres and by a cardiologist in 37%. In the majority of centres, electrical cardioversion was performed using a biphasic defibrillator (85.1%). Antiarrhythmic drugs were routinely prescribed prior to electrical cardioversion by 54.3% of hospitals. For pharmacological cardioversion in patients with no or minimal heart disease, the majority of centres (63.1%) chose intravenous flecainide or propafenone, whereas vernakalant was used by 35% of centres in patients with no or minimal-to-moderate structural heart disease. Most centres (71.7%) used a mandatory strategy of 3 weeks of oral anticoagulation prior to elective cardioversion in patients AF > 48 h, but 28.3% performed immediate cardioversion after a transoesophageal echocardiogram. Many centres are now performing electrical cardioversion on treatment with novel oral anticoagulants (up to 23.6% of cardioversions).
Place, publisher, year, edition, pages
2013. Vol. 15, no 6, 915-918 p.
Medical and Health Sciences
Research subject Cardiology
IdentifiersURN: urn:nbn:se:uu:diva-201280DOI: 10.1093/europace/eut143ISI: 000319468300030PubMedID: 23709570OAI: oai:DiVA.org:uu-201280DiVA: diva2:626594
Conducted by the Scientific Initiatives Committee, European Heart Rhythm Association (EHRA)2013-06-102013-06-102013-07-01Bibliographically approved